Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Current Treatment Options in Oncology|February 19, 2005
Targeted therapies for gynecologic malignanciesJohnny Hyde, D Scott McMeekin
Gynecologic Oncology|June 14, 2011
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancerLisa M Landrum, Johnny Hyde, Robert S Mannel, et al.
Current Treatment Options in Oncology|February 22, 2003
Endometrial cancer: treatment of nodal metastasesD Scott McMeekin, Todd Tillmanns
The Oncologist|October 9, 2010
Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agentsKatherine M Moxley, D Scott McMeekin
Current Opinion in Obstetrics & Gynecology|February 24, 2006
Consolidation therapy in ovarian cancer: where do we stand?Daynelle D Dearnley, D Scott McMeekin
American Journal of Pharmacology and Toxicology|November 6, 2009
Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het DrugJohnny Hyde, Doris M Benbrook
Gynecologic and Obstetric Investigation|August 1, 2007
A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervixMichael L Pearl, Carolyn M Johnston, D Scott McMeekin
Gynecologic Oncology|April 25, 2006
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology GroupMichael A Bookman, D Scott McMeekin, Paula M Fracasso
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 15, 2013
Distance traveled for treatment of cervical cancer: who travels the farthest, and does it impact outcome?Camille C Gunderson, Elizabeth K Nugent, D Scott McMeekin, et al.
Cancer|October 10, 2003
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group studyDavid Scott Miller, John A Blessing, Samuel S Lentz, et al.
Pageof 8